AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Quarter Return
+9.75%
1 Year Return
+18.84%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$135M
AUM Growth
+$135M
(-0.95%)
Cap. Flow
-$14.5M
Cap. Flow
% of AUM
-10.77%
Top 10 Holdings %
Top 10 Hldgs %
21.49%
Holding
245
New
28
Increased
32
Reduced
137
Closed
15
Top Buys
| 1 |
Merck
MRK
|
$2.73M |
| 2 |
Indivior
INDV
|
$2.36M |
| 3 |
Alphatec Holdings
ATEC
|
$2.06M |
| 4 |
Neurocrine Biosciences
NBIX
|
$1.79M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$1.37M |
Top Sells
| 1 |
BioCryst Pharmaceuticals
BCRX
|
$4.17M |
| 2 |
Pacira BioSciences
PCRX
|
$3.36M |
| 3 |
Pfizer
PFE
|
$3.04M |
| 4 |
United Therapeutics
UTHR
|
$2.96M |
| 5 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$2.13M |
Sector Composition
| 1 | Healthcare | 57.92% |
| 2 | Real Estate | 14.45% |
| 3 | Financials | 7.05% |
| 4 | Industrials | 3.2% |
| 5 | Technology | 2.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Rithm Capital
RITM
$6.57B
| $4.32M | 3.21% | 380,966 | – | – |
|
2
Harmony Biosciences
HRMY
$2.12B
| $3.88M | 2.88% | 97,000 -25,000 | -20% | -$1M |
|
3
Galapagos
GLPG
$2.07B
| $3.12M | 2.32% | 108,500 | – | – |
|
|
4
Merck
MRK
$210B
| $2.73M | 2.03% | +24,000 | New | +$2.73M |
|
|
EFC
5
Ellington Financial
EFC
$1.36B
| $2.6M | 1.93% | 201,602 | – | – |
|
|
6
Neurocrine Biosciences
NBIX
$13.8B
| $2.59M | 1.93% | 22,500 +15,500 | +221% | +$1.79M |
|
7
MGIC Investment
MTG
$6.42B
| $2.54M | 1.89% | 99,379 -15,000 | -13% | -$384K |
|
8
argenx
ARGX
$43.6B
| $2.44M | 1.81% | 4,500 -2,750 | -38% | -$1.49M |
|
|
9
Indivior
INDV
$3.03B
| $2.36M | 1.76% | +242,500 | New | +$2.36M |
|
|
DX
10
Dynex Capital
DX
$1.64B
| $2.32M | 1.72% | 181,492 | – | – |
|
11
BioMarin Pharmaceuticals
BMRN
$11.2B
| $2.28M | 1.7% | 32,500 +16,000 | +97% | +$1.12M |
|
12
Sarepta Therapeutics
SRPT
$1.78B
| $2.25M | 1.67% | 18,000 +10,500 | +140% | +$1.31M |
|
13
Dynavax Technologies
DVAX
$1.19B
| $2.24M | 1.67% | 201,500 +71,500 | +55% | +$797K |
|
|
14
United Therapeutics
UTHR
$13.8B
| $2.24M | 1.67% | 6,250 -8,250 | -57% | -$2.96M |
|
|
RWT
15
Redwood Trust
RWT
$791M
| $2.23M | 1.66% | 288,343 | – | – |
|
16
Amicus Therapeutics
FOLD
$2.34B
| $2.19M | 1.63% | 205,000 +2,500 | +1% | +$26.7K |
|
|
MFA
17
MFA Financial
MFA
$1.05B
| $2.13M | 1.59% | 167,725 | – | – |
|
|
18
Alphatec Holdings
ATEC
$2.35B
| $2.06M | 1.53% | +370,000 | New | +$2.06M |
|
19
Exact Sciences
EXAS
$8.98B
| $2.04M | 1.52% | 30,000 | – | – |
|
20
Invesco QQQ Trust
QQQ
$364B
| $2.04M | 1.52% | 4,182 +925 | +28% | +$451K |
|
21
Invesco NASDAQ 100 ETF
QQQM
$58.8B
| $2.04M | 1.52% | 10,158 +2,259 | +29% | +$454K |
|
22
Royalty Pharma
RPRX
$15.6B
| $1.91M | 1.42% | 67,500 +7,500 | +13% | +$212K |
|
23
Mirum Pharmaceuticals
MIRM
$3.71B
| $1.76M | 1.3% | 45,000 -19,000 | -30% | -$741K |
|
24
Jazz Pharmaceuticals
JAZZ
$7.75B
| $1.73M | 1.28% | 15,500 +4,500 | +41% | +$501K |
|
|
MITT
25
AG Mortgage Investment Trust
MITT
$240M
| $1.57M | 1.17% | 208,879 | – | – |
|